Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 14/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.31 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4194821 | 0.87 | CETP (0.42) | CETPCTSLGRIA2GRIN2A | |
| SCHEMBL4222350 | 0.84 | CETP (0.36) | CETP | |
| SCHEMBL5624474 | 0.83 | TACR1 (0.33) | CTSLDHFR | |
| SCHEMBL5042817 | 0.82 | CETP (0.38) | CETP | |
| SCHEMBL4201491 | 0.81 | CETP (0.38) | CETP | |
| SCHEMBL11947602 | 0.80 | GPBAR1 (0.35) | GRIA2GRIN2ADHFR | |
| SCHEMBL17414295 | 0.79 | CETP (0.35) | CETP | |
| SCHEMBL17414275 | 0.78 | DHFR (0.33) | DHFR | |
| SCHEMBL4502464 | 0.77 | CRHR1 (0.36) | CETPLTC4S | |
| SCHEMBL14602960 | 0.77 | CETP (0.35) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410275-B2 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-8410275-B2 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-8410275-B2 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-20120225874-A1 | BICYCLIC DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2012-09-06 | — | — | US | disclosed |
| US-20120225874-A1 | BICYCLIC DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2012-09-06 | — | — | US | disclosed |
| US-20120225874-A1 | BICYCLIC DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2012-09-06 | — | — | US | disclosed |
| US-8232403-B2 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2012-07-31 | — | — | US | disclosed |
| US-8232403-B2 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2012-07-31 | — | — | US | disclosed |
| US-8232403-B2 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2012-07-31 | — | — | US | disclosed |
| US-20090227580-A1 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2009-09-10 | — | — | US | disclosed |
| US-20090227580-A1 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2009-09-10 | — | — | US | disclosed |
| US-20090227580-A1 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2009-09-10 | — | — | US | disclosed |
| EP-2024356-A1 | BICYCLIC DERIVATIVES AS CETP INHIBITORS | Novartis AG (CH) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007128568-A1 | BICYCLIC DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007128568-A1 | BICYCLIC DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227580-A1 | Bicyclic derivatives as CETP inhibitors | CETP, LCAT, CES1 | CETP 1/4885CTSL 347/4885GRIA2 4659/4885 |
| US-20120225874-A1 | BICYCLIC DERIVATIVES AS CETP INHIBITORS | CETP, LCAT, CES1 | CETP 1/4885CTSL 347/4885GRIA2 4659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.